Roy van der Meel
- Biomaterials top 0.5%
- Nanoparticle-Based Drug Delivery 18
- Molecular Biology top 1%
- RNA Interference and Gene Delivery 27
- Advanced biosensing and bioanalysis techniques 15
- Extracellular vesicles in disease 6
- Glycosylation and Glycoproteins Research 3
- Cancer Research top 2%
- Immunology top 2%
- Immunotherapy and Immune Responses 4
- Pharmaceutical Science top 1%
-
- Nanoplatforms for cancer theranostics 7
-
- Monoclonal and Polyclonal Antibodies Research 6
- Co-authors
- Pieter R. CullisJayesh A. KulkarniDominik WitzigmannSam ChenRaymond M. SchiffelersTwan LammersWillem J. M. MulderYang Shi
- Journals
- Journal of Controlled Release (10 papers)Nature Nanotechnology (6 papers)Advanced Drug Delivery Reviews (3 papers)
- Partner nations
- NetherlandsCanadaGermany
In The Last Decade
Roy van der Meel
51 papers receiving 7.8k citations
Hit Papers
Peers
Comparison fields: 5 of 136
- Biomaterials 1.8k
- Molecular Biology 5.6k
- Cancer Research 964
- Immunology 1.1k
- Pharmaceutical Science 297
Countries citing papers authored by Roy van der Meel
This map shows the geographic impact of Roy van der Meel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy van der Meel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy van der Meel more than expected).
Fields of papers citing papers by Roy van der Meel
This network shows the impact of papers produced by Roy van der Meel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy van der Meel. The network helps show where Roy van der Meel may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Roy van der Meel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 43 | |
| 2 | 2024 | 13 | |
| 3 | 2023 | 1 | |
| 4 | Engineering cytokine therapeuticsbreakdown → | 2023 | 132 |
| 5 | 2021 | 16 | |
| 6 | The current landscape of nucleic acid therapeuticsbreakdown → | 2021 | 934 |
| 7 | 2021 | 11 | |
| 8 | 2021 | 42 | |
| 9 | 2020 | 25 | |
| 10 | 2020 | 21 | |
| 11 | 2020 | 147 | |
| 12 | Smart cancer nanomedicinebreakdown → | 2019 | 946 |
| 13 | The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugsbreakdown → | 2019 | 1160 |
| 14 | 2018 | 11 | |
| 15 | PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation timebreakdown → | 2016 | 506 |
| 16 | 2015 | 41 | |
| 17 | 2014 | 14 | |
| 18 | 2012 | 97 | |
| 19 | 2011 | 28 | |
| 20 | 2011 | 34 |
About Roy van der Meel
Roy van der Meel is a scholar working on Biomaterials, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 51 papers that have together received 7.9k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (27 papers), Nanoparticle-Based Drug Delivery (18 papers), Advanced biosensing and bioanalysis techniques (15 papers), Nanoplatforms for cancer theranostics (7 papers), Extracellular vesicles in disease (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Immunotherapy and Immune Responses (4 papers) and Glycosylation and Glycoproteins Research (3 papers). The work is most often cited by research in Biomaterials (1.8k citations), Molecular Biology (5.6k citations) and Cancer Research (964 citations). Roy van der Meel has collaborated with scholars based in Netherlands, Canada and Germany. Frequent co-authors include Pieter R. Cullis, Jayesh A. Kulkarni, Dominik Witzigmann, Sam Chen, Raymond M. Schiffelers, Twan Lammers, Willem J. M. Mulder, Yang Shi, Fabian Kießling and Pieter Vader. Their work appears in journals such as Journal of Controlled Release, Nature Nanotechnology, Advanced Drug Delivery Reviews, Nanomedicine and Molecular Pharmaceutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.